Why the study?
The molecular pathogenesis of myxofibrosarcoma remains poorly understood, diagnosis is challenging without specific immunohistochemical markers, and systemic treatment outcomes in metastatic disease remain poor.
Design
Review
Authors
Loading...
MFS molecular pathogenesis remains poorly understood; leaves open need for genomic studies to identify targets.
Key points are not available for this paper at this time.
Vanni et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: